Psoriasis as a systemic disease

Clinics in Dermatology

Volumn 32, Issue 3, 2014, Pages 343-350

  Grozdev, Ivan ^a   Korman, Neil ^b   Tsankov, Nikolai ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANGIOTENSINOGEN; CYCLOSPORIN; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ANTIGEN; METHOTREXATE; PIOGLITAZONE; PLACEBO; SIMVASTATIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALCOHOLISM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; CROHN DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG EMBOLISM; MORTALITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; TH1 CELL; TH17 CELL; THROMBOPHLEBITIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS; IMMUNOLOGY; INFLAMMATION; MENTAL DISORDERS; METABOLIC SYNDROME X;

CARDIOVASCULAR DISEASES; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; HUMANS; HYPERTENSION; INFLAMMATION; MENTAL DISORDERS; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PSORIASIS; RISK FACTORS;

EID: 84899087479     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.11.001     Document Type: Note

References (107)

1. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005, 141:1537-1541.
2. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
3. National Psoriasis Foundation Psoriasis statistics Retrieved from, Accessed cited July 10, 2009. http://www.psoriasis.org/about/stats.
4. Mrowietz U., Reich K. Psoriasis-new insights into pathogenesis and treatment. Dtsch Arztebl Int 2009, 106:11-18.
5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982-986.
6. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006, 20:52-55.
7. Puig-Sanz L. Psoriasis, a systemic disease?. Actas Dermosifiliogr 2007, 98:396-402.
8. Haglund E., Bremander A.B., Petersson I.F., et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011, 7:943-948.
9. Wilson F.C., Icen M., Crowson C.S., McEvoy M.T., Gabriel S.E., Kremers H.M. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based stud. Arthritis Rheum 2009, 61:233-239.
10. Alenius G.M., Stenberg B., Stenlund H., et al. Inflammatory joint manifestations are prevalent in psoriasis: Prevalence study of joint and axial involvement in psoriatic patient, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002, 29:2577-2582.
11. National Psoriasis Foundation National Psoriasis Foundation 2009 Survey Panel Snapshot Retrieved from. http://www.psoriasis.org/research/survey-panels/current-survey-panel.
12. Zachariae H., Zachariae R., Blomquist K., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from Nordic Quality of Life Study. Acta Derm Venereol 2002, 82:108-113.
13. Nair R., Henseler T., Jenish S., Stuart P., Bichakjian C., Lenk W. Evidence for two psoriasis susceptibility loci (HLA and 17 q) and two novel candidate regions (16 q and 20 P) by genome-wide scan. Hum Mol Genet 1997, 6:1349-1356.
14. Lee F., Bellary S., Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990, 85:962-963.
15. Nair R.P., Stuart P., Henseler T., Jenisch S., Chia N.V., Westphal E., et al. Localization of psoriasis-susceptibility locus PSORS1 to 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000, 66:1833-1844.
16. Hampe J., Schreiber S., Shaw S.H., Lau K.F., Bridger S., Macpherson A.J., et al. A genome-wide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999, 64:808-816.
17. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009, 2:231-237.
18. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb 2005, 12:295-300.
19. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006, 298:321-328.
20. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007, 157:68-73.
21. Cohen A.D., Sherf M., Vidavsky L., Vardy D.A., Shapiro J., Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008, 216:152-155.
22. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol 2007, 56:629-634.
23. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. J Invest Dermatol 2005, 125:61-67.
24. Dreiher J., Weitzman D., Davidovici B., Shapiro J., Cohen A.D. Psoriasis and dyslipidaemia: A population-based study. Acta Derm Venereol 2008, 88:561-565.
25. Cohen A.D., Gilutz H., Henkin Y., Zahger D., Shapiro J., Bonneh D.Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007, 87:506-509.
26. McDonald C.J., Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978, 99:469-475.
27. Ena P., Madeddu P., Glorioso N., Cerimele D., Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985, 40:199-205.
28. Stern R.S., Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988, 91:197-201.
29. Pearce D.J., Morrison A.E., Higgins K.B., Crane M.M., Balkrishnan R., Fleischer A.B., et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005, 16:319-323.
30. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
31. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., Troxel A.B. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009, 129:2411-2418.
32. Prodanovich S., Kirsner R.S., Kravetz J.D., Ma F., Martinez L., Federman D.G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009, 145:700-703.
33. Mehta N.N., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J 2010, 31:1000-1006.
34. Stern R.S., Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011, 131:1159-1166.
35. Mallbris L., Akre O., Granath F., Yin L., Lindelof B., Ekbom A., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19:225-230.
36. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829-835.
37. Bessis D. Severe psoriasis: beyond the skin, what are the risks of not treating the disease?. Ann Dermatol Venereol 2008, 135(Suppl. 5):S285-S289.
38. Wolf R., Wolf D., Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999, 17:423-430.
39. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986, 172:298-304.
40. Poikolainen K., Reunala T., Karvonen J., Lauharanta J., Karkkainen P. Alcohol intake: A risk factor for psoriasis in young and middle aged men?. Bmj 1990, 300:780-783.
41. Morse R.M., Perry H.O., Hurt R.D. Alcoholism and psoriasis. Alcohol Clin Exp Res 1985, 9:396-399.
42. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005, 141:1527-1534.
43. Poikolainen K., Karvonen J., Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999, 135:1490-1493.
44. Kurd S.K., Troxel A.B. Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol 2010, 146:891-895.
45. Gupta M.A., Gupta A.K. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: Epidemiology and management. Am J Clin Dermatol 2003, 4:833-842.
46. Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998, 139:846-850.
47. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005, 141:1537-1541.
48. Gupta M.A., Gupta A.K., Kirkby S., Weiner H.K., Mace T.M., Schork N.J., et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988, 124:1052-1057.
49. Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011, 20:303-307.
50. Mehta N.N., Yu Y., Saboury B., Foroughi N., Krishnamoorthy P., Raper A., et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18 F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): A pilot study. Arch Dermatol 2011, 147:1031-1039.
51. Dowlatshahi E.A., Kavousi M., Nijsten T., et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: The Rotterdam study. J Invest Dermatol 2013, 133:2347-2354.
52. Armstrong A.W., Voyles S.V., Armstrong E.J., Fuller E.N., Rutledge J.C. A tale of two plaques: Convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011, 20:544-549.
53. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
54. Robert C., Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999, 341:1817-1828.
55. Rizova H., Nicolas J.F., Morel P., et al. The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 1994, 7:1-13.
56. Kourosh A.S., Miner A., Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett 2008, 13:1-5.
57. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263:517-527.
58. Uyemura K., Demer L.L., Castle S.C., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996, 97:2130-2138.
59. Methe H., Brunner S., Wiegand D., Nabauer M., Koglin J., Edelman E.R. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005, 45:1939-1945.
60. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006, 116:1218-1222.
61. Takahashi H., Tsuji H., Hashimoto Y., Ishida-Yamamoto A., Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010, 35:645-649.
62. Zaba L.C., Cardinale I., Gilleaudeau P., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
63. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
64. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999, 99:855-860.
65. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17:699-706.
66. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44:1293-1303.
67. Canavese M., Altruda F., Ruzicka T., et al. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies?. J Dermatol Sci 2010, 58:171-176.
68. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004, 93:39-43.
69. George J. Mechanisms of disease: The evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2008, 5:531-540.
70. Gotsman I., Gupta R., Lichtman A.H. The influence of the regulatory T lymphocytes on atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2493-2495.
71. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
72. Kagen M.H., McCormick T.S., Cooper K.D. Regulatory T cells in psoriasis. Ernst Schering Res Found Workshop 2006, 56:193-209.
73. Flisiak I., Chodynicka B., Porebski P., Flisiak R. Association between psoriasis severity and transforming growth factor beta(1) and beta(2) in plasma and scales from psoriatic lesions. Cytokine 2002, 19:121-125.
74. Flisiak I., Zaniewski P., Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers 2008, 13:549-556.
75. Leivo T., Leivo I., Kariniemi A.L., Keski-Oja J., Virtanen I. Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. Br J Dermatol 1998, 138:57-62.
76. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85:e17-e24.
77. Mallat Z., Gojova A., Marchiol-Fournigault C., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934.
78. Alexandroff A.B., Pauriah M., Camp R.D., Lang C.C., Struthers A.D., Armstrong D.J. More than skin deep: Atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009, 161:1-7.
79. Spah F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008, 159:10-17.
80. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
81. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
82. Ward N.L., Loyd C.M., Wolfram J.A., Diaconu D., Michaels C.M., McCormick T.S. Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol 2011, 164:750-758.
83. Wang Y., Gao H., Loyd C.M., Fu W., Diaconu D., Liu S., et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol 2012, 132:2067-2075.
84. Trayhurn P. The biology of obesity. Proc Nutr Soc 2005, 64:31-38.
85. Hamminga E.A., van der Lely A.J., Neumann H.A., et al. Chronic inflammation in psoriasis and obesity: Implications for therapy. Med Hypotheses 2006, 67:768-773.
86. Campfield L.A., Smith F.J., Guisez Y., et al. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995, 269:546-549.
87. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316:924-929.
88. Davidovici B.B., Sattar N., Prinz J., Puig L., Emery P., Barker J.N., et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010, 137:1785-1796.
89. Yoo H., Kim S.J., Kim Y., et al. Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways. Int J Biochem Cell Biol 2007, 39:1248-1259.
90. Zaina S., Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. Curr Opin Lipidol 2003, 14:483-489.
91. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007, 117:2362-2368.
92. Kasperska-Zajac A., Brzoza Z., Rogala B. Platelet function in cutaneous diseases. Platelets 2008, 19:317-321.
93. Ludwig R.J., Schultz J.E., Boehncke W.H., et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004, 122:830-836.
94. Gisondi P., Girolomoni G. Psoriasis and atherothrombotic diseases: Disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009, 35:313-324.
95. Barton B.E. The biological effects of interleukin 6. Med Res Rev 1996, 16:87-109.
96. Guzik T.J., Hoch N.E., Brown K.A., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460.
97. Boehncke S., Salgo R., Garbaraviciene J., et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: Results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011, 25:1187-1193.
98. Shirinsky I.V., Shirinsky V.S. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 2007, 57:529-531.
99. Wolkenstein P., Revuz J., Roujeau J.C., et al. Psoriasis in France and associated risk factors: Results of a case-control study based on a large community survey. Dermatology 2009, 218:103-109.
100. Naseri M., Hadipour A., Sepaskhah M., Namazi M.R. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: A double-blind, randomized, placebo-controlled study. Niger J Med 2010, 19:58-61.
101. Shafiq N., Malhotra S., Pahndhi P., et al. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005, 44:328-333.
102. Ghazizadeh R., Shimizu H., Tosa M., Ghazizadeh M. Pathogenetic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010, 7:284-289.
103. Prodanovich S., Ma F., Taylor J.R., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005, 52:262-267.
104. Solomon D.H., Massarotti E., Garg R., Liu J., Canning C., Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
105. Ryan C., Leonardi C.L., Krueger J.G., et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA 2011, 306:864-871.
106. Kimball A.B., Bensimon A.G., Guerin A., et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011, 12:51-62.
107. Greenberg J.D., Kremer J.M., Curtis J.R., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.